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Abstract
Background: For population based biorepositories to be of use, rigorous quality control and
assurance must be maintained. We have designed and validated a panel of polymorphisms for
individual sample identification consisting of 36 common polymorphisms that have been implicated
in a wide range of diseases and an additional sex marker. This panel uniquely identifies our
biorepository of approximately 20,000 samples and would continue to uniquely identify samples in
biorepositories of over 100 million samples.
Methods: A panel of polymorphisms associated with at least one disease state in multiple
populations was constructed using a cut-off of 0.20 or greater confirmed minor allele frequency in a
European Caucasian population. The fingerprinting assay was tested using the MALDI-TOF mass
spectrometry method of allele determination on a Sequenom platform with a panel of 28 Caucasian
HapMap samples; the results were compared with known genotypes to ensure accuracy. The
frequencies of the alleles were compared to the expected frequencies from dbSNP and any
genotype that did not achieve Hardy Weinberg equilibrium was excluded from the final assay.
Results: The final assay consisted of the AMG sex marker and 36 medically relevant
polymorphisms with representation on each chromosome, encompassing polymorphisms on
both the Illumina 550K bead array and the Affymetrix 6.0 chip (with over a million polymorphisms)
platform. The validated assay has a P(ID) of 6.132 × 10
-15 and a Psib(ID) of 3.077 × 10
-8. This assay
allows unique identification of our biorepository of 20,000 individuals as well and ensures that as
we continue to recruit individuals they can be uniquely fingerprinted. In addition, diseases such as
cancer, heart disease diabetes, obesity, and respiratory disease are well represented in the
fingerprinting assay.
Conclusion: The polymorphisms in this panel are currently represented on a number of
common genotyping platforms making QA/QC flexible enough to accommodate a large number of
studies. In addition, this panel can serve as a resource for investigators who are interested in the
effects of disease in a population, particularly for common diseases.
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With the advent of genome wide association studies large
bio-banks will become the stepping stones to tomorrow's
medicine. The genome wide association study (GWAS)
has recently proved its value with replicable findings for
diseases such as coronary artery disease, prostate cancer,
and diabetes [1], and many more discoveries are expected
in the near future. To determine these associations,
studies have relied on large populations of well char-
acterized cases and controls often combining several
study populations in order to approach statistical
significance [1]. Once these associations have been
found in well characterized target cohorts, the findings
must be replicated in a population based cohort before
translation into clinical practice [2]. These cohorts will
come from the large population based cohorts being
collected in places like the Marshfield Clinic [3] and
Vanderbuilt [4] and Kaiser Permenente [5].
For these biorepositories to be of use rigorous quality
control and assurance must be maintained to minimize
sample identification errors. The quality of the nation's
biobanks is such a priority that the National Cancer
Institute has established an Office of Biorepositories and
Biospecimen Research with the specific mission to
develop standards and determine the best practices and
protocols for the burgeoning field [5]. Erroneous sample
identification and mistaken sample handling can stay
hidden for many years compromising results; this
problem has plagued researchers that work with cell
culture for years [6,7].
One strategy for reducing errors in sample identification
is to increase the automation of sample acquisition,
storage and handling. The PMRP repository used a semi-
automated system of sample handling for recruitment in
2001 which included the Marshfield Clinic's practice
management and laboratory information systems for
subject recruitment and sample collection. PMRP cur-
rently uses the Nautilus
® (Thermo Fischer, PA, USA)
b i o s p e c i m e nt r a c k i n gs y s t e mw i t ha ni n t e g r a t e dp l a t e
reader for tracking of sample storage [8]. Other larger
biorepositories such as the UK biobank have chosen to
automate sample collection and storage to a larger
degree in order to further reduce the possibility of
incorrect sample identification [9]. While automation
does rule out some possible sample identification
mistakes it does not eliminate all potential error from
the process as technicians are still involved in sample
acquisition and processing. In addition, automation
does not inform the quality of the specimen to help
research personnel determine the usefulness of the
sample nor does it provide a process for correcting and
identifying errors that have occurred during previous
sample collections. Even when samples are collected,
processed, and aliquotted with minimal human hand-
ling, results from collaborating institutions must be
checked to ensure no identification errors occurred in
transferring either the samples or the data between
institutions. Therefore it is imperative that an initial
characterization of a sample includes both unique
identifiers and measures of quality. This is particularly
true when genotypic and phenotypic information are
being combined in large association studies.
One method of identification would be to rely on markers
developed for forensic applications. A number of different
SNP panels have been developed to identify subjects; these
panelsrangefroma21SNPmultiplextoa52SNPmultiplex
that has been validated in different populations [10-13].
However,theuseofforensicpanelsforsampleidentification
may create ethical and legal challenges. Increasingly
biorepositories have also chosen to create their own SNP
panelsforqualitycontrolandassurance.TheWellcomeTrust
used a 38 SNP panel for quality control of the samples used
for the genome wide association study of seven common
diseases [14]. While any of these panels could be used for
sample identification and tracking, they are not useful in
characterizing the population in relation to polymorphisms
already known to be associated with disease.
In an effort to balance the needs of quality control and
genomic research we have designed and validated a
panel of polymorphisms for individual sample identifi-
cation that have been implicated in a wide range of
diseases. In this paper we describe our process for
designing the panel as well as the ability of this panel to
uniquely discriminate samples using known allele
frequencies. We also demonstrate how this panel may
be used in the future by researchers investigating
common diseases such as heart disease and obesity.
Methods
SNP panel design
The inclusion criteria for a polymorphism to be
considered for use in the fingerprinting assay were as
follows. First the polymorphism must have a confirmed
minor allele frequency of approximately 0.20 or greater
in a European Caucasian population, this allele fre-
quency was chosen based on a theoretical assay of 34
polymorphisms, an average allele frequency of 0.20 was
needed to uniquely identify 20,000 subjects. Second, the
polymorphism it must be medically relevant; defined as
having been associated with at least one disease state in
multiple populations. Finally, the polymorphism must
be easily detectable using the Sequenom platform
(Sequenom, San Diego, CA, USA).
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isms all of the investigators within the Marshfield Clinic
Research Foundation were asked to submit polymorph-
isms that were of interest. Garnering a list of 116
polymorphisms, these were tested with the above criteria
before proceeding to assay design. In addition, this list
was supplemented with polymorphisms from the
PharmGKB [15] and Genetic Association Database [16].
The minor allele frequency in a Caucasian population
was then confirmed using the published allele frequen-
cies in dbSNP [17] to ensure that the polymorphism was
common enough to be considered for inclusion in the
panel. A Medline [18] search for disease associations was
then performed for each polymorphism that met the
frequency requirement. Any polymorphism that had an
association with at least one disease in two separate
preferably Caucasian populations was then allowed to
progress to the next step.
Finally each polymorphism was masked using SNPmas-
ker and evaluated for ease of adaptation to the
Sequenom platform. The remaining polymorphisms
were used in the Sequenom Assay Design 3.1 [19]
program to develop a large multiplex assay. Several
assays with between 33–39 polymorphisms as well as
the sex marker AMG were created. A single assay of 40
total polymorphisms with at least one polymorphism on
each chromosome was chosen for validation.
This study was reviewed and approved by the Marshfield
Clinic Institutional Review Board.
Allele detection
Allele detection was carried out using the MALDI-TOF
mass spectrometry method of allele determination on a
Sequenom platform. Briefly this method of detection
depends on the different molecular weights of the
polymorphic regions to determine the allele. A multi-
plexed PCR reaction is carried out on genomic DNA to
amplify regions of interest. These products are then
annealed with primers that are in the region directly
adjacent to the polymorphism and a single base pair
primer extension reaction is performed to generate the
allele specific products. The products are then placed on
a proprietary chip and analyzed using MALDI-TOF mass
spectrometry and Sequenom Typer 3.4 software [20] to
make the allele determination. A list of the PCR and
detection primers is provided in additional file 1. Any of
the automatic genotype determinations that were flagged
as lower confidence or that the program failed to
automatically determine were then double checked by
a human to determine if manual allele calls could be
made.
Assay validation
The 40 polymorphism fingerprinting assay was tested
initially on a panel of 28 Caucasian HapMap samples
from the CEPH population provided by Coriell. Our
fingerprinting assay contained 32 polymorphisms that
had been previously genotyped in this population; we
compared our results with those released through the
dbSNP Genotyping detail [21] or the cancer500 web site
[22] to ensure genotyping accuracy. Further validation
for accuracy and precision was completed by repeated
assays using anonymous DNA extracted with our
protocol from a Caucasian population. One final
population of a further set of 21 CEPH samples was
used to ensure accuracy of both the automated and
manual genotype calls. Polymorphisms that were not
automatically determined at least 80% of the time were
excluded from the assay. The frequencies of the alleles
and genotypes obtained with the assay were compared to
the expected frequencies from dbSNP. Finally, the
polymorphisms in the assay were checked for disagree-
ment with Hardy Weinberg equilibrium; any poly-
morphism that failed was excluded from the final assay.
Determination of individual discriminatory power
The expected allele frequencies were used to determine
the potential power of the assay using the following
equations for the probability of identity. We calculated
the probability of identity [P(ID)] for the assay using two
different equations. The first equation assumes the
population is random and uses the product rule with
Hardy-Weinberg equilibrium assumptions [23], and the
second equation is more conservative and assumes the
population is composed of siblings [24]. We performed
these calculations assuming independent assortment of
the alleles.
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Results
Polymorphism selection and assay design
116 polymorphisms were submitted by investigators from
the Marshfield Clinic Research Foundation, 6 polymorph-
isms were taken from the PharmGKB VIP list and poly-
morphisms in chromosome 9, 18, 21, and 22 were obtained
from the Disease Association Database providing an addi-
tional 12 polymorphisms. All of these polymorphisms were
then evaluated for the inclusion criteria (Figure 1). 27
candidates failed because the allele frequency in a Caucasian
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failed to pass the criteria of medical relevance. Finally, three
morepolymorphismswereeliminatedaftermaskingbecause
ofincompatibilitywiththeSequenomsystem.Theremaining
77 polymorphisms were placed in the Sequenom Assay
Design program and a single 40 polymorphism assay was
created. The assay includes 39 polymorphisms that are
medically relevant (see additional file 2 for the references
used to determine medical relevance) with at least one
polymorphism on each chromosome and the AMG gender
marker. The polymorphisms used in the assay as well as the
chromosome and associated geneare provided along with at
least one associated disease state (Table 1).
Assay validation
A total of 3 polymorphisms (rs1693782, rs4444903, and
rs1800012) did not achieve 80% automated call rate and
accuracy in the assay. The finalized validated assay
consists of 37 polymorphisms, with the AMG sex marker
and 36 medically relevant polymorphisms with repre-
sentation on each chromosome (Table 1).
Since one of the goals of this assay is to provide a quality
control mechanism for genotyping using a whole
genome scan we assessed the panel for polymorphisms
that were represented on either the Affymetrix 6.0 chip
(with over a million polymorphisms) or the Illumina
550K bead set (with over half a million polymorph-
isms). The fingerprint encompasses 16 polymorphisms
that are on the Illumina 550K assay and 12 that are on
the Affymetrix 6.0 chip assay with 7 polymorphisms in
common to both platforms (Table 2).
Power of discrimination
Preliminary analysis of a hypothetical SNP panel
suggested that 34 polymorphisms of an average minor
allele frequency of 0.20 along with a sex marker would
be needed to individually identify a biorepositiory of
20,000 samples. Here we have created a panel of 36
polymorphisms with an average MAF of 0.354667 and a
sex marker. For the validated assay we obtained a P(ID)
of 6.132 × 10
-15 and a Psib(ID) of 3.077 × 10
-8.
To further ensure the assay could be used to uniquely
identify our population we calculated the P(ID) and
Psib(ID) of the assay assuming that only polymorphisms
located farther than 50 megabases apart segregated
independently. Finally we calculated the probability of
i d e n t i t yu s i n go n l yt h ep o l y m o r p h i s m sf o u n do nt h e
Illumina and Affymetrix platforms, using only the
polymorphisms limited to one or the other of these
platforms individual identification of samples should be
possible. Even using the most conservative Psib(ID) from
thepolymorphismsontheAffymetrixplatform,3.0×10
-3,
meaning 60 individuals in the population may not
have unique patterns (Table 3).
Common Disease Coverage
The second goal of the fingerprinting panel is to provide
a resource for investigating the genetic components of
common diseases. In order to ensure that the fingerprint
assay developed here encompasses a wide range of
diseases we compared the coverage of the assay with the
28 focus areas from healthy people 2010 [25]. Many of
the focus areas such as cancer, heart disease, diabetes,
obesity, and respiratory disease are well represented in
the fingerprinting assay. Heart disease, the most pre-
valent disease in the PMRP population and a high
priority disease for healthy people 2010 is represented
with 10 polymorphisms that may be important in the
development or severity of disease (table 4). Based on
Figure 1
Schematic representation of the development the
DNA fingerprinting assay. Schematic representation of
the inclusion criteria for a polymorphism to be considered
for the fingerprinting assay and the number of
polymorphisms that failed each step.
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minimal detectable odds ratio for these polymorphisms
is between 1.5 and 3.2 with the most prevalent disease
(heart disease) having the lowest detectable odds ratio of
1.5 [26] (table 4).
As would be expected from a collection of medically
relevant polymorphisms many of the genes represented
in the assay share common pathways or substrates.
Examples of pathways with more than one represented
gene include the renin-angiotensinogen pathway with
three genes (ACE, AGTR1, EGF), and the cholesterol
maintenance pathway with four genes in the assay
(APOB, CETP, LDLR, LPL, and FABP2). In addition,
neurotransmitter pathways are represented by four
different genes; two serotonin receptors (COMT,
DRD3) and two genes in the dopamine pathway
(HTR2A, HTR1B). Furthermore three genes in the assay
use folate as a substrate (MTHFD1, ENOSF1, CBS).
Discussion
As we usher in the era of genomic medicine, population
based biorepositories linked to growing medical records
will become important for translating genetic discoveries
into medical practice. For these repositories to be of use,
stringent quality control and assurance mechanisms
must be established. Furthermore these repositories
become the ideal place to test genetic associations that
have been discerned in case control cohorts to determine
Table 1: Initial design of unique fingerprint assay using medically relevant polymorphisms
Polymorphism Caucasian MAF Chromosome Gene Disease Associated with Polymorphism*
rs1137101 0.449 1p31 LEPR Obesity, Insulin Resistance, Non-Hodgkin's lymphoma
rs486907 0.408 1q25 RNASEL Prostate cancer
rs1042031 0.208 2p24 APOB Cardiovascular disease, Dislipidemia
rs231775 0.379 2q33 CTLA4 Multiple Sclerosis, Autoimmune Disease
rs5186 0.348 3q21 AGTR1 Metabolic syndrome, Aortic aneurism, Left-ventricular hypertrophy
rs6280 0.35 3q13.3 DRD3 Schizophrenia
rs1693482 0.477 4q21 ADH1C Alcohol dependence, Coronary heart disease
rs1799883 0.373 4q28 FABP2 Metabolic syndrome, Type 2 diabetes
rs4444903 0.392 4q25 EGF Cancer
rs4961 0.208 4p16.3 ADD1 Hypertension, Coronary artery disease
rs1042714 0.467 5q31 ADRB2 Obesity, COPD
rs351855 0.283 5q35.1 FGFR4 Cancer
rs5370 0.242 6p24 EDN1 Asthma, sleep apnea
rs6296 0.322 6q13 HTR1B substance abuse
rs2227983 0.25 7p12.3 EGFR Cancer
rs213950 0.492 7q31.2 CFTR Cystic fibrosis
rs7493 0.237 7q21.3 PON2 Myocardial infarction
rs328 0.273 8p22 LPL Left ventricular hypertrophy
rs2383206 0.475 9p21 Coronary artery disease
rs1800861 0.25 10q11.2 RET Hirschsprung disease, Thyroid cancer
rs1801253 0.283 10q24 ADRB1 Insulin Resistance
rs2227564 0.341 10q24 PLAU Alzheimer's disease, asthma
rs1799750 0.433 11q22.3 MMP1 Endometriosis, Osteolysis, Rheumatoid authritis
rs1063856 0.342 12p13.3 VWF Hypertension
rs6313 0.438 13q14 HTR2A Psychiatric disorders
rs2236225 0.396 14q24 MTHFD1 Neural tube defects
rs1800588 0.333 15q21 LIPC Coronary artery disease
rs243865 0.198 16q13 MMP2 Cancer
rs4673 0.342 16q24 CYBA Coronary artery disease
rs708272 0.478 16q21 CETP Coronary artery disease
rs1800012 0.188 17q21.3 COL1A1 Osteoporosis
rs4291 0.354 17q23 ACE Depression, Alzheimer's disease
rs4792311 0.331 17p11 ELAC2 Prostate cancer
rs16430 0.37 18p11.3 ENOSF1/TYMS Cancer
rs601338 0.391 19q13.3 FUT2 Infection susceptibility
rs688 0.45 19p13.2 LDLR Alzheimer's disease, Coronary artery disease
rs7121 0.458 20q13.3 GNAS Obesity, Cancer
rs234706 0.333 21q22 CBS Oral cleft defects
rs4680 0.483 22q11.21 COMT Schizophrenia, ADHD
AMG (del) 0.5 Xp22.3 AMG Sex Marker
Polymorphisms (rs1693482, rs4444903, rs1800012) were excluded from the final assay because of validation failures.
*Annotated bibliography of the publications used to determine medical relevance is in additional file 2.
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paper we described the development of a single assay of
36 medically relevant polymorphisms and a sex marker
that will be used to uniquely identify samples in the
Personalized Medicine Research Project cohort and
simultaneously provide investigators with information
on medically relevant polymorphisms for a wide array of
diseases. Furthermore we determined which of these
polymorphisms were present on the two most popular
platforms used for whole genome association, Illumina
and Affymetrix, to ensure the panel would be adequate
for determining sample handling errors in shipping and
genotyping.
Quality control and assurance of biorepositories
involves an integrated program of both minimization
of potential errors and testing for potential sample
problems to quickly rectify errors. The PMRP bioreposi-
tory incorporates automation through an in house
developed system for specimen acquisition and the
Nautilis
® system for specimen tracking. However, auto-
m a t i o ni so n l yo n ea s p e c to fac o m p r e h e n s i v es a m p l e
assurance program. This newly developed assay will be
used for determining the ability of the DNA to be used
for genotyping. In addition it will allow us to determine
an estimate of error rates in our sample acquisition. We
will compare the genotyped sex with the expected sex
from the medical record to ensure a match. In addition,
we will use known trios and pedigrees to compare
individual samples for instances of non-maternity and
non-paternity as potential indicators of sample identifi-
cation error. Because of the unique ability of PMRP to re-
contact subjects, as samples are exhausted or potential
errors are identified, new samples can be acquired and
verified using existing information to confirm sample
identity. This ensures that each sample can be correctly
attributed to an individual each time a new sample is
drawn.
The number of polymorphisms used for our assay
compares favourably to panels that have been used for
other applications. In order to ensure that our goal of
using the fingerprinting assay for individual identifica-
tion of the PMRP cohort was met, we determined the
P(ID) and Psib(ID) of the assay. Even using the most
conservative estimates of the assay we can correctly
identify approximately three million samples. SNP
panels used for forensic applications have ranged from
20 to 52 SNPs [10,11,13]. A test of SNP panels used to
identify cell lines included panels of 80, 60, 40, and 20
SNPs with the conclusion that 20 SNPs did not
discriminate adequately however any of the most
frequent 40 polymorphisms would provide adequate
power of discrimination. From this assumption an assay
of 34 polymorphisms with individual identification
ability was developed [12].
Our assay is unique not only because we used only
medically relevant polymorphisms but also because we
developed the assay with a polymorphism on every
chromosome and included polymorphisms on a number
of popular genotyping platforms. Even using the most
Table 2: Fingerprinting polymorphisms on either the Illumina or
Affymetrix platform
Polymorphism Illumina Platform
550K bead set
Affymetrix Platform
6.0 chip set
rs1137101 X
rs486907 X
rs1042031 X
rs6280 X
rs5370 X
rs6296 X
rs213950 X
rs7493 X
rs2227564 X X
rs1063856 X
rs6313 X X
rs2236225 X X
rs1800588 X
rs243865 X
rs4673 X
rs4792311 X X
rs688 X X
rs7121 X
rs234706 X
rs4680 X X
AMG (del) X X
TOTAL 16 12
Table 3: Probability of identity for the validated fingerprinting assay
Polymorphism group Total number
of Polymorphisms
Probability
of identity P(ID)
Probability of identity
(siblings) Psib(ID)
Validated fingerprinting assay 37 6.132 × 10
-15 3.077 × 10
-08
Conservative validated fingerprinting assay* 32 4.906 × 10
-13 2.947 × 10
-07
Polymorphisms on the Illumina platform (550K) 16 5.844 × 10
-07 4.075 × 10
-04
Polymorphisms on the Affymetrix platform (6.0 chip) 12 2.649 × 10
-05 3.004 × 10
-03
*The conservative estimate includes only polymorphisms that are greater than 50 centimorgans (cM) apart to ensure independent assortment of each
polymorphism.
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morphisms on the Affymetrix platform we would have
few potential incorrectly identified samples, and these
samples could easily be further identified by ascertaining
the genotype calls polymorphisms in linkage disequili-
brium with polymorphisms that are on the fingerprint-
ing assay. This ensures that any sample handling errors
that are potentially introduced in shipping the samples
or receiving data from other laboratories can be detected
when genotyping results are entered into our database.
By comparing returned genotypes with previously
determined genotypes provides a quality check for any
data that is generated externally. Using the assay in this
manner provides an opportunity to correct sample errors
or questionable calls from genotyping before samples
are linked with phenotypic medical information.
Because of the dual nature of the assay several potential
limitations arise. The stringent dual criteria of medical
relevance and high minor allele frequency have the
potential to limit the usefulness of the assay for both
goals. One of the limitations of the assay we developed is
that only the European Caucasian MAF was considered
as a selection criterion. The PMRP biospecimens are
overwhelmingly Caucasian therefore this is appropriate
for our application, however this emphasis may decrease
the applicability of this assay to other populations.
Using the allele frequencies for Asian and African
populations from dbSNP 6 polymorphisms in the
assay fell below 10% MAF in Africans and 2 polymorph-
isms were below 10% in Asian populations. Identifica-
tion panels developed for forensic applications generally
consider a large number of different ethnicities when
creating the panel to ensure correct identifications across
populations [10,11,13]. At this time, we have no reason
to believe that the choice of medically relevant poly-
morphisms inherently biased the assay toward the
Caucasian population and preliminary analysis of
estimated allele frequencies in other populations
would suggest the fingerprinting assay to be robust for
other populations. Myles et al. [27] recently tested allele
frequencies across populations for disease associated
SNPs and determined they vary no more across popula-
tions than randomly chosen SNPs. However any poly-
morphism can have varying allele frequencies among
different populations and until the allele frequencies for
our polymorphisms are verified in other populations we
cannot determine how useful it would be for non-
Caucasians.
Another limitation for the assay is that the medical
relevance of the assay could be limited. Many medically
relevant polymorphisms are less frequent in the popula-
tion than 20%. For instance polymorphisms in the ApoE
alleles are highly medically relevant with many pleio-
tropic effects on disease [28], however they have a minor
allele frequency of 0.18 and 0.02 [21], and therefore
were excluded from consideration. In addition, because
of the evolving nature of gene disease discovery it is
possible that some of the polymorphisms we included in
the assay will later be determined to have little medical
value. For instance, the polymorphism chosen in the RET
gene while associated with disease, has only been
associated in small studies [29,30]. Furthermore, newly
associated medically relevant polymorphisms such as the
cancer susceptibility locus on chromosome 8q24 [31]
were not included in the assay because assay construc-
tion began before this region was known. Finally,
because we focused on including polymorphisms from
a range of diseases, it is likely that investigators will need
to perform more genotyping for any comprehensive
study of disease-gene interactions.
By using a limited number of commonly occurring
polymorphisms as an identification panel and main-
taining strict access to individual genotyping results, the
panel avoids the potential legal and ethical burden of
using a forensic panel, does not expose the population to
increased identification risk, and may provide insight
into population wide allele frequencies. As with any
population wide genotyping, the manner of reporting
the genotypes must be taken into consideration to
Table 4: Common diseases in the PMRP cohort and polymorphism coverage of these diseases
Disease PMRP prevalence (%)* Associated
polymorphisms
in the fingerprint
Healthy People
2010 Focus area
Minimal detectable odds
ratio based on disease
prevalence*
Cardiovascular disease 7518 (41.2%) 10 12 1.5
Obesity 6927 (38%) 7 19 <3.2
COPD 6123 (33.6%) 2 24 <3.2
Arthritis 4814 (26.4%) 3 2 <3.2
Asthma 2186 (13.7%) 4 24 <3.2
Cancer (all sites) 2073 (11.4%) 8 3 <3.2
Diabetes 1734 (9.5%) 4 5 <3.2
*from McCarty, Mukesh, Giampetro and Wilke 2007 [24]
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genotypes created by this fingerprinting assay will be
publicly reported only as population wide allele
frequencies. Disease associated polymorphisms have
been reported in this manner for a number of different
populations, most recently the NHANES III population
[32] and the CLUE I and CLUEII populations [33]. Even
with the recent revelations regarding the ability to
discern individual DNA contribution to a mixture, the
number of potentially reported polymorphisms from this
assay, 36, is well under the smallest estimate of 10,000
needed to discern an individual in a mixture of 0.1%[34].
Individual genotypes are stored in a secure server and not
publically available. The PMRP consent form and study
guidelines require any investigator that requests indivi-
dual genomic information for any reason to have an IRB
approved protocol before data is released [3].
Despite the potential limitations of the panel, we have
demonstrated that an identification panel can be created
using only medically relevant polymorphisms. Such
panels could be created with disease specific polymorph-
isms and used in the future not only to identify samples
but potentially to access an individual's genetic risk of a
disease We are currently using this panel for QA/QC
purposes on the DNA samples in the PMRP repository. In
the future we intend to test these polymorphisms for
association with disease in the entire PMRP population to
determine their medical relevance in our population. In
the future this panel or other rationally designed panels
can be used on large populations not only as a quality
control measure but also to begin to translate the results
from the large genome wide studies into clinical practice.
Because this panel includes polymorphisms that are
relevant in a wide range of diseases the information
gained from genotyping the entire PMRP population will
be used to help facilitate population based research.
Conclusion
We created a single panel of 36 somatic polymorphisms
and a sex marker with the ability to discriminate
individuals in a large biorepository (of potentially over
100,000,000 samples) using only common medically
relevant polymorphisms. These polymorphisms are
currently represented on a number of common genotyp-
ing platforms making QA/QC flexible enough to
accommodate a large number of studies. In addition
this panel can serve as a resource for investigators who
are interested in the effects of disease in a population
particularly for common diseases.
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